Abbott Laboratories stock holds firm as diagnostics and medical devices support earnings

Abbott Laboratories stock is underpinned by steady demand for diagnostics and medical devices, with recent quarterly figures showing mid-single-digit revenue growth and solid cash generation across key segments.

Abbott Laboratories stock is backed by a broad healthcare portfolio that has delivered resilient earnings in recent quarters, with the US-based medical devices and diagnostics group (ISIN US0028241000) reporting billions of dollars in quarterly revenue from its diversified operations. According to the companys most recent full-year and quarterly figures for 2025, Abbott generated more than $40 billion in annual sales, with mid-single-digit growth versus the prior year driven by cardiovascular, diabetes care, and diagnostic products. For investors, the breadth of Abbott Laboratories business lines - spanning diagnostics, medical devices, nutrition, and established pharmaceuticals - provides a degree of earnings stability even as individual segments face cyclical or competitive pressures.

Revenue grows in mid-single digits

Abbott Laboratories business is structured across four core segments: diagnostics, medical devices, nutrition, and established pharmaceuticals, each contributing materially to group revenue. In its most recent reported fiscal year, the company stated that consolidated revenue was slightly above $40 billion, representing a mid-single-digit percentage increase compared with the roughly $38 billion recorded in the preceding fiscal year, reflecting steady growth despite the normalization of COVID-19 testing demand. This revenue expansion was driven partly by continued adoption of diabetes care devices and cardiovascular interventions, which together contributed several billion dollars of incremental sales versus the prior period, as well as stable demand in the nutrition division.

Diagnostics remain a central revenue pillar for Abbott, with the segment contributing well over $10 billion in annual sales according to the 2025 report, even after COVID-19 testing volumes declined from their peak. Within diagnostics, core laboratory and point-of-care platforms posted low- to mid-single-digit growth over the year, partially offsetting the anticipated contraction in pandemic-related testing revenue, and demonstrating the underlying strength of the companys installed base. Medical devices, which include electrophysiology, structural heart, and diabetes care, accounted for more than $15 billion of revenue in the same period, marking a high-single-digit increase year on year as procedure volumes recovered and new product launches gained traction in key markets.

Abbott Laboratories reported that its nutrition segment generated approximately $8 billion of annual revenue, broadly flat to slightly higher than the prior year, reflecting the ongoing recovery of its infant formula business in the United States and steady demand for adult nutrition products internationally. Established pharmaceuticals, focused primarily on emerging markets, contributed around $4 billion to group sales, posting low-single-digit growth compared with the previous fiscal year as currency effects and pricing dynamics moderated the impact of volume increases. Taken together, these segment trends underpin the overall mid-single-digit top-line expansion that Abbott Laboratories achieved over the latest reported year, highlighting the strength of its diversified healthcare portfolio.

Operating margin supports cash generation

Beyond revenue, Abbott Laboratories financial performance in its latest annual report showed healthy profitability, with operating margin in the mid- to high-teens and net income in the multi-billion-dollar range, supported by disciplined cost control and a favorable mix shift toward higher-margin devices and diagnostics. The company indicated that adjusted earnings per share for the fiscal year were in the mid-dollar range, rising by a mid- to high-single-digit percentage compared with the prior year as modest revenue growth combined with margin improvement. This earnings progression allowed Abbott to continue funding research and development at a rate of several billion dollars annually while maintaining dividend payments to shareholders.

Abbott Laboratories cash flow metrics also underscore the companys financial resilience. In the most recent annual period, the group generated operating cash flow of well over $7 billion, with free cash flow after capital expenditure comfortably exceeding $5 billion, providing room for ongoing investment in manufacturing, clinical trials, and product launches. Compared to the prior fiscal year, operating cash flow grew by a mid-single-digit percentage, broadly in line with earnings growth, while capital expenditure remained disciplined at around $2 billion, focused on capacity expansion for key devices and diagnostics platforms and modernization of production facilities.

The balance sheet remains a point of stability for Abbott Laboratories. Total debt stood in the low- to mid-teens of billions of dollars at the end of the latest reported year, while cash and short-term investments amounted to several billion dollars, leaving net debt at manageable levels relative to EBITDA. On a net-debt-to-EBITDA basis, Abbott was positioned comfortably below 2.0x, consistent with an investment-grade capital structure and providing flexibility for bolt-on acquisitions in high-growth therapeutic areas or technologies. The companys disciplined approach to leverage and liquidity is an important consideration for shareholders, particularly in a sector where regulatory and reimbursement changes can affect cash flow visibility.

Earnings guidance for the current year

Abbott Laboratories regularly provides full-year earnings guidance, offering investors a forward-looking view on expected performance. In its latest guidance for the current fiscal year, the company projected adjusted earnings per share in the range of roughly $4 to $4.10, implying mid-single-digit growth from the prior year baseline, which was in the region of $3.90 per share. This guidance assumes continued expansion in medical devices and diabetes care, a further recovery in nutrition, and ongoing normalization of COVID-related testing volumes within diagnostics, while factoring in currency headwinds and inflationary cost pressures.

At the segment level, Abbott indicated that devices and diabetes care are expected to remain key growth drivers, with double-digit revenue increases targeted in certain product categories, while diagnostics and nutrition are forecast to deliver low- to mid-single-digit gains. Established pharmaceuticals are guided for modest growth, reflecting emerging market dynamics and competition from generics. The companys guidance also incorporates expected investments in research and development, including funding for clinical programs in cardiology, neuromodulation, and diabetes technologies, as well as spending on digital health and data integration capabilities that support its device portfolio.

Dividend policy is another component of Abbott Laboratories investor offering. The company has a track record of annual dividend increases, and in the most recent year, it raised its quarterly dividend by a mid-single-digit percentage, maintaining a payout ratio in the range of 40% to 50% of adjusted earnings. This level is designed to balance shareholder returns with retained earnings for reinvestment. The combination of recurring dividends and moderate share repurchases, funded from strong cash flow, contributes to Abbott Laboratories total shareholder return profile and signals confidence in its long-term earnings power.

FreeStyle Libre drives diabetes growth

Abbott Laboratories diabetes care business, anchored by its FreeStyle Libre continuous glucose monitoring system, has been one of the companys most dynamic franchises in recent years. According to the companys latest sales breakdown, the FreeStyle Libre portfolio generated more than $5 billion in annual revenue, representing strong growth from the roughly $4 billion recorded the year before, as adoption expanded across both type 1 and type 2 diabetes populations in multiple geographies. This roughly billion-dollar year-on-year increase underscores the acceleration of wearable sensor technologies in diabetes management and positions Abbott as a leading player in this segment.

The FreeStyle Libre system combines sensors, readers, and software applications that allow patients and healthcare providers to monitor glucose levels continuously and adjust treatment more precisely. Abbott has progressively expanded the product line, offering multiple generations of sensors with longer wear times, improved accuracy, and integration with smartphone apps. In the most recent year, the company introduced enhancements that support broader interoperability with digital health platforms and insulin delivery devices, expanding the system ecosystem. Such upgrades are expected to support ongoing double-digit revenue growth in diabetes care, even as competition intensifies.

From a profitability perspective, the diabetes care portfolio is an important contributor to Abbott Laboratories margin profile. The company indicated that the segment operates at attractive gross margin levels due to the recurring nature of sensor usage and the scalability of manufacturing. As volumes have risen, economies of scale have helped to offset pricing pressures and increased R&D spending. The strong performance of FreeStyle Libre and related products has also encouraged Abbott to invest further in data analytics and decision-support tools, aiming to enhance the value proposition for patients, clinicians, and payers.

Abbott Laboratories stock and market valuation

Abbott Laboratories stock represents an equity claim on this diversified healthcare business and its future cash flows. The company is listed on the New York Stock Exchange, with the ticker ABBOTT commonly referenced in market data tools, and has a market capitalization in the range of tens of billions of dollars. In recent trading, Abbott Laboratories stock has oscillated within a 52-week range that spans from roughly the low $90s to around $120 per share, reflecting broader market sentiment on healthcare, interest rate expectations, and company-specific news flows. At recent prices around the mid-point of this range, the implied price-to-earnings multiple based on the companys guided adjusted EPS lies in the mid-20s, consistent with a premium valuation for an established growth-oriented healthcare issuer.

Compared with sector peers in medical devices and diagnostics, Abbott Laboratories valuation typically trades at a moderate premium to the diversified healthcare average, reflecting its strong cash flow, recurring revenue streams, and leading positions in select high-growth categories such as continuous glucose monitoring and structural heart devices. For example, when its adjusted EPS outlook for the current year is contrasted with the share price near the mid-$100 range, the earnings yield appears somewhat lower than that of certain large-cap pharmaceutical peers but similar to other global medtech companies with comparable growth trajectories. This relative valuation context is one factor that market participants consider when assessing Abbott Laboratories stock.

Beyond pure earnings multiples, investors also look at dividend yield and free-cash-flow yield. With a quarterly dividend that sum to more than $2 per share annually, Abbott Laboratories offers a dividend yield in the low-single-digit percentage range at current prices, while free cash flow relative to market capitalization suggests a mid-single-digit percentage free-cash-flow yield. The relationship between these metrics, and the companys track record of dividend growth and reinvestment, feeds into views on the stock as a blend of growth and income, rather than a high-yield or deep-value play.

Abbott Laboratories stock at a glance

• Company: Abbott Laboratories Inc.
• ISIN: US0028241000
• Ticker: NYSE: ABT
• Trading venue: NYSE
• Price (as of 18 July 2026, 16:00 EST): 103.50 USD
• Market capitalization: 180,000,000,000 USD (as of 18 July 2026)
• Sector / Industry: Health Care / Health Care Equipment & Supplies
• Index membership: S&P 500
• Next earnings date: 20 July 2026